[1]张亚玲,王琳,王敬贤,等.双膦酸盐治疗骨质疏松症与总死亡率相关性的meta分析[J].中华老年骨科与康复电子杂志,2020,(05):304-311.[doi:10.3877/cma.j.issn.2096-0263.2020.05.010]
　ZhangYaling,WangLin,Wang Jingxian,et al.The relationship between bisphosphonates and total mortality in patients with osteoporosis: A Meta-Analysis[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2020,(05):304-311.[doi:10.3877/cma.j.issn.2096-0263.2020.05.010]
点击复制

双膦酸盐治疗骨质疏松症与总死亡率相关性的meta分析()
分享到：

中华老年骨科与康复电子杂志[ISSN:1674-3911/CN:11-9292/R]

卷:
期数:
2020年05期
页码:
304-311
栏目:
Meta分析
出版日期:
2020-10-05

文章信息/Info

Title:
The relationship between bisphosphonates and total mortality in patients with osteoporosis: A Meta-Analysis
作者:
张亚玲1; 王琳1; 王敬贤2; 何新霞1
053000 衡水市人民医院全科医学科1，关节运动医学科2
Author(s):
ZhangYaling1;  WangLin1;  Wang Jingxian2;  He Xinxia1
1Department of general?practice?medicine, 2Department of joint sports medicine, Hengshui people’s Hospital, Hengshui 053000, China
关键词:
骨质疏松症;  双膦酸盐;  总死亡率
Keywords:
Osteoporosis;  Bisphosphonates;  Total mortality
DOI:
10.3877/cma.j.issn.2096-0263.2020.05.010
文献标志码:
A
摘要:
目的 系统评价临床随机对照试验是否能够证明双膦酸盐类药物的应用与骨质疏松症患者的死亡率降低相关。方法 依据Meta分析要求，对CBM、CNKI、MEDLINE、PubMed、Springer、Embase、万方、维普、Cochrane Library、中国科技论文统计与分析网、专利数据库等进行检索，严格评价纳入以双膦酸盐药物作为主要干预措施治疗骨质疏松症的临床随机对照实验研究文献，并收录有效的相关的数据资料，检索年限从建库至2020年5月。采用NOS文献质量评价标准对符合纳入排除标准的文献进行质量评价。采用RR值及其95%可信区间评估关联强度。根据是否存在异质性，采用固定效应模型合并效应量，并根据单因素敏感性分析法进行敏感性分析。结果 最终纳入21篇文献，受试者共42 849例，双膦酸盐组患者22 605例，死亡855例，安慰剂组20 244例，死亡880例。双膦酸盐治疗骨质疏松症与总死亡率相关性的为RR=0.949（95% CI：0.866，1.040，P=0.264）。阿仑膦酸盐治疗骨质疏松症与总死亡率相关性的为RR=0.996（95% CI：0.705，1.407，P=0.982），伊班膦酸盐为RR=0.802（95% CI：0.496，1.298，P=0.369），利塞膦酸盐为RR=0.915（95% CI：0.757，1.105，P=0.354），唑来膦酸盐为RR=0.898（95% CI：0.770，1.047，P=0.168），尚未发现双磷酸盐治疗骨质疏松症与总死亡率的关联性。结论 经meta分析发现双膦酸盐治疗骨质疏松症患者的总死亡率未见明显降低。
Abstract:
Objective To systematically evaluate whether clinical randomized controlled trials can demonstrate that bisphosphonates, especially zoledronic acid, are associated with reduced mortality in patients with osteoporosis. Methods According to the requirements of meta-analysis, CBM, CNKI, MEDLINE, PubMed, Springer, EMBASE, Wanfang, VIP and Cochrane were analyzed Library, China Science and Technology Papers Statistics and analysis network, patent database, etc. were searched to strictly evaluate the included clinical randomized controlled trials with bisphosphonates as the main intervention measures in the treatment of osteoporosis, and included effective related data. The retrieval period was from the establishment of the database to may 2020. The NOS standard was used to evaluate the quality of the literatures that met the inclusion and exclusion criteria. RR and its 95% confidence interval were used to evaluate the association strength. According to the existence of heterogeneity, the fixed effect model was used to merge the effect amount, and the single factor sensitivity analysis method was used to analyze the sensitivity. Results A total of 21 articles including 42, 849 subjects, 22, 605 patients in the bisphosphonate group, 855 patients died, 20, 244 patients in the placebo group and 880 deaths in the placebo group were analyzed. The correlation between bisphosphonate therapy and total mortality was 0.949 (95% CI: 0.866, 1.040, P=0.264). The correlation between alendronate and total mortality was 0.996 (95% CI: 0.705, 1.407, P=0.982), ibandronate was RR=0.802 (95% CI: 0.496, 1.298, P=0.369), risedronate was RR=0.915 (95% CI: 0.757, 1.105, P=0.354) and zoledronate was RR=0.898 (95% CI: 0.770, 1.047, P=0.168). There was no association between bisphosphonate therapy and total mortality. Conclusion The meta-analysis showed that bisphosphonates did not reduce the overall mortality of patients with osteoporosis.

相似文献/References:

[1]马晓龙,刘强,吴斗,等.骨质疏松显微骨折早期发生发展过程的实验研究[J].中华老年骨科与康复电子杂志,2016,(03):129.[doi:10.3877/cma.j.issn.2096-0263.2016.03.001]
　Ma Xiaolong,Liu Qiang,Wu Dou,et al.Experimental study of osteoporotic microsurgery fractures in the early development process[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2016,(05):129.[doi:10.3877/cma.j.issn.2096-0263.2016.03.001]
[2]崔红旺,蒋电明.骨细胞程序性死亡在骨质疏松中作用的研究进展[J].中华老年骨科与康复电子杂志,2016,(03):181.[doi:10.3877/cma.j.issn.2096-0263.2016.03.011]
　Cui Hongwang,Jiang Dianming.Effect of the programmed cell death of osteocyte on osteoporosis[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2016,(05):181.[doi:10.3877/cma.j.issn.2096-0263.2016.03.011]
[3]李子怡,李玉坤.OPG/RANK/RANKL信号通路在骨质疏松症中的研究进展和应用[J].中华老年骨科与康复电子杂志,2017,(02):124.[doi:10.3877/cma.j.issn.2096-0263.2017.02.012]
　Li Ziyi,Li Yukun.Researching progress and application of OPG-RANK-RANKL signaling pathway in osteoporosis[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2017,(05):124.[doi:10.3877/cma.j.issn.2096-0263.2017.02.012]
[4]雷涛,申勇.老年骨质疏松性椎体骨折若干问题的探讨[J].中华老年骨科与康复电子杂志,2017,(04):248.[doi:10.3877/cma.j.issn.2096-0263.2017.04.010]
　Lei Tao,Shen Yong..A brief discussion of osteoporotic vertebral fractures in elderly patients[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2017,(05):248.[doi:10.3877/cma.j.issn.2096-0263.2017.04.010]
[5]马树伟.球囊扩张椎体成形术治疗急性与亚急性期骨质疏松椎体压缩骨折的疗效对比[J].中华老年骨科与康复电子杂志,2017,(06):341.[doi:10.3877/cma.j.issn.2096-0263.2017.06.005]
　Ma Shuwei.Clinical efficacy of percutaneous kyphoplasty in the treatment of acute and subacute phase of osteoporotic vertebral compression fractures[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2017,(05):341.[doi:10.3877/cma.j.issn.2096-0263.2017.06.005]
[6]刘伟,傅光涛,胡旭民,等.唑来膦酸治疗绝经后骨质疏松发生脆性骨折的临床研究[J].中华老年骨科与康复电子杂志,2017,(06):351.[doi:10.3877/cma.j.issn.2096-0263.2017.06.007]
　Liu Wei,Fu Guangtao,Hu Xumin,et al.Analysis in postmenopausal osteoporosis patients with fragility fracture during zoledronic acid treatment[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2017,(05):351.[doi:10.3877/cma.j.issn.2096-0263.2017.06.007]
[7]梁伟,吴斗,赵恩哲,等.皮质厚度在骨质疏松性髋部骨折中的应用研究[J].中华老年骨科与康复电子杂志,2018,(03):184.[doi:10.3877/cma.j.issn.2096-0263.2018.03.012]
　Liang Wei,Wu Dou,Zhao Enzhe,et al.Application research of Cortical thickness in osteoporotic hip fractures[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2018,(05):184.[doi:10.3877/cma.j.issn.2096-0263.2018.03.012]
[8]谢亚明,谢国盛,林蒙,等.网袋成形术与椎体后凸成形术治疗骨质疏松性椎体压缩骨折的早期疗效比较[J].中华老年骨科与康复电子杂志,2018,(04):202.[doi:10.3877/cma.j.issn.2096-0263.2018.04.003]
　Xie Yaming,Xie Guosheng,Lin Meng,et al.Early clinical outcome of vesselplasty and kyphoplasty in treatment of osteoporotic vertebral compression fractures[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2018,(05):202.[doi:10.3877/cma.j.issn.2096-0263.2018.04.003]
[9]吴石磊 刘勇 邵增务 田青. 骨组织细胞外泌体对骨代谢作用的研究现状[J].中华老年骨科与康复电子杂志,2018,(05):308.
　Wu Shilei,Liu Yong,Shao Zengwu,et al. Research status of bone tissue-derived exosomes on bone metabolism[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2018,(05):308.
[10]王建华.骨质疏松症治疗药物的分类与用药选择[J].中华老年骨科与康复电子杂志,2019,(05):297.[doi:10.3877/cma.j.issn.2096-0263.2019.05.010]
　Wang Jianhua.Classification and selection of drugs for treating osteoporosis[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2019,(05):297.[doi:10.3877/cma.j.issn.2096-0263.2019.05.010]
[11]邢浩,刘强,吴斗,等.双膦酸盐治疗股骨非典型性骨折的研究进展[J].中华老年骨科与康复电子杂志,2018,(02):118.[doi:10.3877/cma.j.issn.2096-0263.2018.02.010]
　Bisphosphonates and atypical femur fractures femur[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2018,(05):118.[doi:10.3877/cma.j.issn.2096-0263.2018.02.010]
[12]郜振武 吴斗 高敏 朱剑 陈晨 孙吉平 刘强. 骨质疏松性骨折的药物治疗策略与选择[J].中华老年骨科与康复电子杂志,2018,(05):317.
　Gao Zhenwu,Wu Dou,Gao Min,et al. The drug treatment for strategy and selection of osteoporotic fracture[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2018,(05):317.
[13]李沫,王海旸,王丽娟,等.老年骨质疏松常用治疗药物的研究现状及展望[J].中华老年骨科与康复电子杂志,2019,(06):365.[doi:10.3877/cma.j.issn.2096-0263.2019.06.011]
　Li Mo,Wang Haiwei,Wang Lijuan,et al.The present and progress of common drug therapy in treating senile osteoporosis[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2019,(05):365.[doi:10.3877/cma.j.issn.2096-0263.2019.06.011]

更新日期/Last Update: 2020-10-10